9mw0813
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 26, 2021 (NCT05324592)
Timeline
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AANTAGONIST
VEGFA antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05324774 | Phase 3 | Feb 28, 2022 | Mabwell |
| NCT05324592 | Phase 1 | Feb 26, 2021 | Mabwell |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mabwell | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1